Statement on Omicron Subvariants, Pre-Exposure Prophylaxis, and Therapeutic Management of Nonhospitalized Patients With COVID-19 Published

National Institute of Allergy and Infectious Diseases sent this bulletin at 11/10/2022 10:42 AM EST

NIH COVID-19 Treatment Guidelines

Statement on Omicron Subvariants, Pre-Exposure Prophylaxis, and Therapeutic Management of Nonhospitalized Patients With COVID-19 Published

The Centers for Disease Control and Prevention reports that the prevalence of certain SARS-CoV-2 Omicron subvariants circulating in the United States has continued to rise in the past few weeks. Some of these subvariants (e.g., BQ.1, BQ.1.1, BA.4.6, BF.7, BA.2.75.2) are likely to be resistant to the anti-SARS-CoV-2 monoclonal antibodies tixagevimab plus cilgavimab (Evusheld), while others (e.g., BQ.1, BQ.1.1) are likely to be resistant to bebtelovimab.

The COVID-19 Treatment Guidelines Panel has published a statement that provides interim recommendations on the use of tixagevimab plus cilgavimab for SARS-CoV-2 pre-exposure prophylaxis (PrEP) and on the use of bebtelovimab for the treatment of COVID-19. This statement also provides strategies to facilitate the use of ritonavir-boosted nirmatrelvir (Paxlovid) and remdesivir in patients with COVID-19.

Please visit the COVID-19 Treatment Guidelines website to read the full statement.

Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help.

This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).